UPC_APP_27016/2025

NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

Prozessuale & UnteranträgeVerfahrensführungsanordnungenThe Hague LDApplication Rop 333—

Übersicht Entscheidungen Dokumente Zeitverlauf

Parteien

Kläger

Arbutus Biopharma Corporation
Genevant Sciences GmbH

Vertreter: Markus van Gardingen (Not specified)

Beklagte

Moderna, Inc.(Moderna Group)
ModernaTX, Inc.(Moderna Group)
Moderna Belgium S.R.L.(Moderna Group)
Moderna Italy S.R.L.(Moderna Group)
Moderna France SASU(Moderna Group)
Moderna Biotech UK Limited(Moderna Group)
Moderna Switzerland GmbH(Moderna Group)
Moderna Poland SP. Z.O.O.(Moderna Group)
Moderna Portugal Unipessoal LDA(Moderna Group)
Moderna Sweden AB(Moderna Group)
Moderna Netherlands B.V.(Moderna Group)
Moderna Biotech Spain SL(Moderna Group)
Moderna Denmark ApS(Moderna Group)
Moderna Germany GmbH(Moderna Group)
Moderna Norway AS(Moderna Group)

Vertreter: Ruben Laddé (Not specified); Joachim Renken (Not specified)

Richter

Not SpecifiedJudge-Rapporteur (The Hague Local Division)

Patente

EP 2 279 254
EP 4 241 767

CPC-Codes: C07J9/00, A61P31/14, A61K9/1271, C12N15/111, C12N2310/14, C12N15/113, A61K9/1272, A61P35/00, A61K31/713, C12N2320/32, A61P31/12, C12N15/1137…

Sektor: Biotechnology

Ausgang

Nur prozessual

Eingereicht: —

Erste Entscheidung: 12. Juni 2025

Sprache: —